Cargando…

Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves’ disease

Detalles Bibliográficos
Autores principales:	Gill, Harinder, Hwang, Yu-Yan, Tse, Eric
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018268/ https://www.ncbi.nlm.nih.gov/pubmed/20467745 http://dx.doi.org/10.1007/s00277-010-0983-4

Ejemplares similares

Antithyroid treatment improves thrombocytopenia in a young patient with Graves’ disease
por: Faienza, Maria Felicia, et al.
Publicado: (2020)

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

Primary autoimmune thrombocytopenia and co-existing Graves’ disease: Role of radioiodine-131
por: Jung, Rayamajhi Sampanna, et al.
Publicado: (2014)

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence
por: Liu, Jia, et al.
Publicado: (2017)

Antithyroid drugs in Graves’ disease: Are we stretching it too far?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2016)

Antithyroid Drugs in the Management of Graves' Disease: A Friend and Foe
por: Butt, Muhammad I, et al.
Publicado: (2023)

Changes in the Ocular Parameters of Patients with Graves’ Disease after Antithyroid Drug Treatment
por: Lee, Je-Sang, et al.
Publicado: (2021)

Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
por: Rho, Jung Gi, et al.
Publicado: (2021)

Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism
por: Weng, Huan, et al.
Publicado: (2023)

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons
por: Rajput, Rajesh, et al.
Publicado: (2013)

Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs
por: Li, Jiaxi, et al.
Publicado: (2023)

Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023)

The thyroid function of Graves' disease patients is aggravated by depressive personality during antithyroid drug treatment
por: Fukao, Atsushi, et al.
Publicado: (2011)

Clinical Features and Remission Rate of Pediatric Graves’ Hyperthyroidism Treated With Antithyroid Drug
por: You, Kyusang, et al.
Publicado: (2021)

Early Biochemical Response to Antithyroid Drugs in Graves’ Disease: The Role of Initial Dosing
por: El Kawkgi, Omar M, et al.
Publicado: (2021)

Use of unconventional antithyroid therapy in patients with thiamazole agranulocytosis in the context of the COVID-19 pandemic
por: Alvarez-Gamero, Julio César, et al.
Publicado: (2022)

Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease
por: Liu, Jia, et al.
Publicado: (2017)

Immunosuppressive treatment for immune thrombocytopenia which masked Graves’ disease
por: Baldane, Suleyman, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Antithyroid Drug (Propylthiouracil) Compared to Radioactive Iodine for the Treatment of Graves’ Disease in Ethiopia
por: Mengistu, Habtamu Solomon, et al.
Publicado: (2022)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?
por: Belsing, Tina Z, et al.
Publicado: (2010)

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease
por: Yasuda, Kie, et al.
Publicado: (2017)

Commentary on "Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs"
por: Kim, Minsun
Publicado: (2021)

Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse
por: Wong, Tsz Wai Catherine, et al.
Publicado: (2022)

Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report
por: Yan, Lily D., et al.
Publicado: (2017)

Long-term follow-up result of antithyroid drug treatment of Graves’ hyperthyroidism in a large cohort
por: Jin, Meihua, et al.
Publicado: (2023)

A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment
por: Kim, Hyunsam, et al.
Publicado: (2018)

A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
por: Liu, Xiaomei, et al.
Publicado: (2015)

Commentary on “Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse”
por: Kim, Ji Hyun
Publicado: (2022)

Pregnancy and immune thrombocytopenia: New trends
por: Yavaşoğlu, İrfan, et al.
Publicado: (2020)

Drug-induced immune-mediated thrombocytopenia
por: Singh, Harpreet, et al.
Publicado: (2020)

Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia
por: Scaramucci, Laura, et al.
Publicado: (2013)

Unilateral Graves' Disease
por: Mahalakshmi, VNSSVAMS D, et al.
Publicado: (2019)

Differences in the Treatment Response to Antithyroid Drugs versus Electroconvulsive Therapy in a Case of Recurrent Catatonia due to Graves' Disease
por: Saito, Takahiro, et al.
Publicado: (2012)

Long-Term Antithyroid Drug Treatment of Graves’ Disease in Children and Adolescents: A 20-Year Single-Center Experience
por: Song, Ari, et al.
Publicado: (2021)

Duration of antithyroid drug treatment may predict weight gain after radioactive iodine therapy in patients with Graves’ disease
por: Yotsapon, Thewjitcharoen, et al.
Publicado: (2022)

The study of transcriptome sequencing in childhood immune thrombocytopenia
por: Sun, Congcong, et al.
Publicado: (2019)

Immune Thrombocytopenia Following COVID-19 Vaccination
por: Isaac, Sangeetha, et al.
Publicado: (2022)

Platelet Levels of High- and Mega-Dose Methylprednisolone Treatment in Acute Immune Thrombocytopenia
por: Ayçiçek, Ali
Publicado: (2015)

Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
por: Kwon, Hyemi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v2bso79r96cr95lbk46jm7a91m